RLMD250117C2500
- 0.05
- 0.000.00%
Relmada Therapeutics Newsroom
Relmada Therapeutics Strengthens Leadership With New COO
Relmada Therapeutics Shifts Focus After Study Discontinuation
Relmada Therapeutics Exploring Sale After Lead Program Failure
Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017
Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Express News | Trading Halt: Halted at 7:25:00 A.m. ET - Trading Halt: Halt News Pending
Relmada Shares Continue Downward Spiral After Downgrades
Relmada Cut to Neutral by Mizuho on Phase 3 Study Failure
Mizuho Securities Downgrades Relmada Therapeutics (RLMD) to a Hold
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Relmada Therapeutics Cut to Market Perform From Outperform by Leerink Partners
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Top Midday Decliners
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
Leerink Partners Downgrades Relmada Therapeutics to Market Perform From Outperform, $1 Price Target; Shares Plummet